The purchase of basic infusion tapes in Heilongjiang Province has started!

On February 24, the Heilongjiang Centralized Drug Purchasing Network released the "Announcement on the Centralized Procurement of Basic Infusion in Heilongjiang Province", announcing the launch of the centralized procurement of basic infusion in Heilongjiang Province
.
This time, the products purchased with quantity involved 49 product specifications, including sodium chloride injection, glucose sodium chloride injection, and glucose injection, 3 basic infusion varieties
.
The main body of procurement is the public medical institutions and military medical institutions in the administrative area of ​​Heilongjiang Province
.
In addition, the announcement stipulates that all companies that meet the "application qualifications" and "quotation requirements" are all shortlisted, and a comprehensive scoring system is adopted to determine the companies to be selected
.
The purchase quantity is 80% of the pre-purchased quantity, and the purchaser determines the contract purchase quantity in proportion and completes the purchase proportion in the actual purchase
.
The procurement cycle is 1 year in principle, and can be extended by 1 year depending on the situation
.
During the procurement cycle, dynamic management is implemented for the products in the selected catalogue, including cancelling the qualification for selection, adjusting the selection information (price), and delivering (substitute) products according to relevant regulations
.
Application Qualification Holders of domestic drug marketing authorizations that provide drugs and accompanying services, and national general agents of imported drugs designated by drug marketing authorization holders (for overseas enterprises)
.
The applicant enterprise must meet the following conditions: (1) Listed drugs that fall within the scope of the catalogue of purchased varieties and have obtained a valid domestic registration approval document
.
(2) The annual production capacity of the declared varieties is more than 4 times (inclusive) of the agreed purchase volume
.
(3) The applicant enterprise must ensure that the agreed procurement volume of the selected drugs in the supply area is met within the procurement cycle
.
(4) The applicant enterprise shall abide by the Patent Law, the Anti-Unfair Competition Law and other relevant laws and regulations, and bear corresponding legal responsibilities
.
(5) The declared drugs shall comply with the national drug standards and drug quality standards approved by the State Drug Administration, and shall comply with the "Technical Guiding Principles for Research on Nitrosamine Impurities in Chemical Drugs (for Trial Implementation) issued by the Center for Drug Evaluation of the State Drug Administration.
" ” (No.
1, 2020) to organize production; (6) There is no unqualified quality inspection by the provincial (inclusive) drug supervision and management department within the two years before this centralized drug procurement activity for the declared varieties
.
(7) The declared enterprise has not been included in the current "National Risk Warning List of Pharmaceutical Prices and Untrustworthy Enterprises in Recruitment and Procurement"; there is no violation of the provisions of the "Heilongjiang Province Pharmaceutical Price and Recruitment and Procurement Credit Evaluation System (2020 Version)"
.
The purchased varieties and pre-purchased quantities are as follows: